Prenatal genetic testing is a set of blood tests, ultrasounds, and procedures offered during pregnancy to check whether a baby has certain chromosomal conditions or inherited disorders. These tests fall into two broad categories: screening tests that estimate risk and diagnostic tests that give definitive answers. Professional medical societies now recommend that all pregnant patients be offered genetic screening, regardless of age or risk factors.
Screening Tests vs. Diagnostic Tests
The most important distinction in prenatal genetic testing is the difference between screening and diagnosis. Screening tests use blood samples and ultrasound to estimate the chance that a baby has a condition like Down syndrome. They don’t provide a yes-or-no answer. A result comes back as either “screen negative” (lower risk) or “screen positive” (higher risk). A positive screening result doesn’t mean the baby has the condition. It means further testing is worth considering.
Diagnostic tests, on the other hand, analyze actual fetal cells and can confirm or rule out a condition with near-certainty. These require a procedure, either chorionic villus sampling (CVS) or amniocentesis, that carries a small risk of pregnancy loss, estimated at less than 1 in 500. Many people start with a screening test and only move to a diagnostic procedure if the results show elevated risk.
Carrier Screening for Inherited Conditions
Carrier screening is different from the other tests because it checks the parents’ DNA, not the baby’s. It identifies whether one or both parents carry a gene for a recessive disorder, meaning a condition that only affects a child if both parents pass along the same faulty gene. Standard panels check for cystic fibrosis, sickle cell disease, Tay-Sachs disease, fragile X syndrome, and thalassemia.
Expanded carrier screening is now the recommended approach and tests for dozens of additional conditions, including spinal muscular atrophy and Wilson disease. You can have carrier screening before or during pregnancy. If both partners carry a gene for the same condition, the baby has a 1 in 4 chance of being affected. That information helps you plan next steps with your provider, including whether to pursue diagnostic testing on the pregnancy itself.
First Trimester Screening: Weeks 11 to 13
First trimester screening combines a blood draw with a specialized ultrasound measurement called nuchal translucency, which measures a small fluid-filled space at the back of the baby’s neck. A larger-than-typical measurement can signal an increased risk for chromosomal conditions. The blood test measures two proteins produced during pregnancy. Together, these results are combined with the mother’s age to generate a risk estimate for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).
This screening is done between 11 and 13 weeks of pregnancy. Because timing matters for an accurate nuchal translucency measurement, the window is relatively narrow.
Cell-Free DNA Screening (NIPT)
Cell-free DNA screening, commonly called NIPT (non-invasive prenatal testing), is a blood test that can be done as early as 10 weeks. During pregnancy, fragments of the baby’s DNA circulate in the mother’s bloodstream. NIPT analyzes these fragments to check for extra or missing chromosomes.
NIPT is most commonly used to screen for Down syndrome, Edwards syndrome, and Patau syndrome. It can also detect sex chromosome differences and, in some cases, certain microdeletions (small missing pieces of a chromosome). Its accuracy is notably high. In a study of nearly 69,000 pregnancies, the detection rate was 98.2% for Down syndrome, 96.2% for Edwards syndrome, and 100% for Patau syndrome, with specificity above 99.9% for all three. That means false positives are rare, but they do happen.
Despite its accuracy, NIPT is still a screening test. A high-risk result should be confirmed with a diagnostic procedure before making any decisions. NIPT also performs less reliably for rarer conditions and in certain situations, such as very early gestational age, high maternal body weight, or twin pregnancies.
Second Trimester Screening: Weeks 15 to 20
The quad screen is a blood test done between 15 and 20 weeks that measures four substances: alpha-fetoprotein (a protein made by the baby), hCG (a hormone from the placenta), unconjugated estriol (a form of estrogen produced by both the baby and placenta), and inhibin A (another placental hormone). The levels of these four markers, combined with the mother’s age, help estimate risk for Down syndrome, Edwards syndrome, and neural tube defects like spina bifida and anencephaly.
Elevated alpha-fetoprotein levels can point toward neural tube defects or abdominal wall problems, while a specific pattern of low AFP, low estriol, high hCG, and high inhibin A is associated with Down syndrome. This is one reason the quad screen remains useful even when NIPT is available: NIPT does not screen for neural tube defects.
Diagnostic Testing: CVS and Amniocentesis
When screening results come back with elevated risk, or when parents want a definitive answer, diagnostic testing is the next step. Two procedures are available, each done at a different stage of pregnancy.
Chorionic villus sampling (CVS) is performed between 10 and 13 weeks. A small sample of tissue from the placenta is collected and sent for chromosomal analysis. It offers results earlier in pregnancy, which some families prefer.
Amniocentesis is typically done between 15 and 20 weeks. A thin needle is guided by ultrasound into the uterus to withdraw a small amount of amniotic fluid, which contains fetal cells. Those cells are then analyzed for chromosomal conditions and, in some cases, specific genetic disorders or fetal infections. Amniocentesis can also assess fetal lung maturity later in pregnancy if early delivery is being considered.
Both procedures carry a small risk of pregnancy loss. Recent cohort data places the procedure-related loss rate below 0.5% for both CVS and amniocentesis, which is lower than older estimates that many people still encounter online. A study tracking outcomes found a total pregnancy loss rate of about 1% after CVS and 0.8% after amniocentesis, but when compared to matched control groups of women who did not have procedures, the difference attributable to the procedure itself was minimal.
Choosing Which Tests to Have
No single test does everything. Carrier screening tells you about the parents’ genes. First trimester screening and NIPT estimate the baby’s risk for chromosomal conditions. The quad screen adds neural tube defect detection. Diagnostic tests confirm or rule out conditions with certainty but involve a procedure.
Your choices depend on what information matters most to you and when. Some people want every available data point. Others prefer to start with a simple blood screen and only go further if results warrant it. Some skip screening entirely and go straight to diagnostic testing, particularly if they have a known family history or a previous pregnancy affected by a genetic condition.
The timing of each test shapes your options. First trimester screening and CVS are only available through about 13 weeks. If you’re past that window, NIPT, the quad screen, and amniocentesis remain available into the second trimester. Talking through the sequence early in pregnancy gives you the widest range of choices.
What Results Can and Cannot Tell You
Screening results express risk as a ratio, like 1 in 10,000 or 1 in 150. A “positive” screen doesn’t mean the baby has a condition. It means the estimated risk is above a certain cutoff and further testing is an option. Many people with positive screens go on to have unaffected pregnancies.
Diagnostic results are far more definitive. If amniocentesis or CVS confirms trisomy 21, that result is essentially certain. But even diagnostic tests have limits. They check for specific conditions, not every possible genetic variation. A normal result means the tested conditions were not found, not that the baby is guaranteed to be free of all health issues.
These tests also vary in what they cover. Standard panels focus on the most common chromosomal conditions. Expanded panels and microarray analysis can detect smaller genetic changes, but with that broader net comes a higher chance of finding variations whose significance is unclear. Your provider or a genetic counselor can help you understand what each test will and won’t look for, and what different results would mean for your pregnancy.